Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
NeuBase Therapeutics Inc banner
N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64% Market Closed
Market Cap: €5.4m
Write Note Create Alert Ask AI

NeuBase Therapeutics Inc
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also
Balance Sheet

NeuBase Therapeutics Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Total Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$12.8B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.9B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$9.6B
CAGR 3-Years
20%
CAGR 5-Years
16%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$2.1B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.7B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
5.4m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available
N
What is Intrinsic Value?

See Also

What is NeuBase Therapeutics Inc's Total Receivables?
Total Receivables
0 USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Total Receivables amounts to 0 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.